Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 8/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956400 | 0.85 | TAAR1 (0.39) | TAAR1GAAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29952198 | 0.76 | TAAR1 (0.55) | TAAR1GAAKDM4ESMN1; SMN2HTT | |
| SCHEMBL27577860 | 0.75 | TAAR1 (0.39) | EEDTAAR1GAAKDM4EALDH1A1 | |
| SCHEMBL4243083 | 0.74 | EED (0.41) | EEDTAAR1GAAKDM4EALDH1A1 | |
| SCHEMBL29386736 | 0.74 | EED (0.41) | EEDTAAR1GAAKDM4EALDH1A1 | |
| SCHEMBL7627111 | 0.72 | TAAR1 (0.45) | EEDTAAR1GAA | |
| SCHEMBL31614296 | 0.72 | EED (0.43) | EEDTAAR1GAAKDM4EALDH1A1 | |
| SCHEMBL15352403 | 0.72 | EED (0.40) | EEDTAAR1GAAKDM4EALDH1A1 | |
| SCHEMBL20558278 | 0.72 | EED (0.40) | EEDTAAR1GAAKDM4EALDH1A1 | |
| SCHEMBL3072191 | 0.72 | TAAR1 (0.41) | EEDTAAR1GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | EED 2014/4885TAAR1 2937/4885GAA 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.